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BACKGROUND. Currently, there is no standard treatment for patients with advanced
renal cell carcinoma (RCC) who do not experience a response to ﬁrst-line immu-
notherapy. In the current Phase II study, the authors explored the antitumor
activity of a combination of gemcitabine and oxaliplatin (L-OHP) in this setting.
METHODS. Forty-two patients with RCC who had progressive disease following
immunotherapy received gemcitabine (1000 mg/m2 intravenously on Days 1 and 8
every 21 days) and L-OHP (90 mg/m2 intravenously on Day 1 every 21 days) for a
minimum of 2 cycles before responses were evaluated. Responses to treatment and
toxicity were recorded according to the Response Evaluation Criteria in Solid
Tumors and the National Cancer Institute Common Toxicity Criteria, respectively.
RESULTS. No complete responses were recorded; however, 6 patients experienced
a partial response (14.28%; 95% conﬁdence interval, 5.43–28.5%), 11 patients
(26.19%) had temporary stable disease as a best response, and the remaining 25
patients (59.52%) experienced progression despite receiving treatment. The me-
dian time to disease progression was 2.5 months (mean, 3.86 months; range,
1.5–11.0 months), whereas the median overall survival was 9.5 months (mean,
10.46 months; range, 4.0–22.5 months). With regard to toxicity, treatment generally
was well tolerated, with only one episode of Grade 4 toxicity and expected episodes
of Grade 3 toxicity, including myelosuppression and neuropathy.
CONCLUSIONS. The current results suggest that the combination of gemcitabine
and L-OHP possesses a certain level of activity and an acceptable toxicity proﬁle in
patients with immunotherapy-resistant advanced RCC. Cancer 2004;100:2132–8.
© 2004 American Cancer Society.
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Renal cell carcinoma (RCC) is the seventh leading cause of malig-nancy-related death. It is estimated that there will be approxi-
mately 31,900 patients with newly diagnosed RCC and approximately
11,900 deaths due to RCC this year in the United States alone.1 At the
time of diagnosis, approximately 30% of patients who are diagnosed
with RCC have unresectable and, thus, incurable disease;2 further-
more, approximately 50% of patients with RCC who undergo curative
resection will develop recurrent and/or metastatic disease. Overall,
patients with advanced RCC have a very poor prognosis, with a
median survival of approximately 10 months.3
Due to frequent overexpression of the MDR gene product,
P-glycoprotein,4 RCC typically is a chemoresistant tumor. Conse-
quently, immunotherapy is used as a ﬁrst-line treatment option.5
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Although it has been demonstrated that different
interleukin-2 (IL-2)-based immunotherapy sched-
ules often are active, leading to objective responses
or long-term disease stabilization in  20% of pa-
tients,5–8 at present, there is no standard treatment
for patients with immunotherapy-resistant disease.
Traditional cytotoxic chemotherapeutic regi-
mens fail to affect the natural history of RCC and
thus typically yield poor results. In fact, a compre-
hensive review on these regimens by Yagoda et al. in
1995 revealed an overall response rate of 6% among
4093 patients with advanced RCC who received ad-
equate treatment, with only a slight improvement
(to 14.6%) in a subgroup of patients who were
treated with an antimetabolite (ﬂoxuridine or 5-ﬂu-
orouracil [5-FU]).9 Despite the discovery of a num-
ber of new cytotoxic agents in the last 10 years, the
unsatisfactory state of RCC treatment was no differ-
ent by the year 2000, when Ruiz et al. reviewed
single and multiagent Phase II and III trials that
were performed between 1993 and 1998, enrolling
more than 2300 patients.10
More recently, it has been shown that gemcitab-
ine-containing combinations also exert some antitu-
mor activity in patients with immunotherapy-resistant
advanced RCC.11–20 Herein, we report the results of a
single-institution Phase II study in which we evaluated
the antitumor activity and toxicity of a combination of
gemcitabine with the platinum derivative oxaliplatin
(L-OHP).
MATERIALS AND METHODS
Study Design and Statistical Considerations
The objective of the current single-institution Phase II
study was to assess the antitumor activity and toxicity
of the combination of gemcitabine and L-OHP in a
population of patients with immunotherapy-resistant
advanced RCC. We used a three-stage Phase II design
that was adopted previously in the same setting by
other investigators.14
The study regimen was to be rejected if the esti-
mated response rate was  5% and accepted as active
if the estimated response rate was  20%. Using an 
error of 0.05 (representing the probability of accepting
the regimen as active even with a response rate  5%)
and a  error of 0.10 (representing the probability of
rejecting the regimen as active even with a response
rate  20%), the ﬁrst stage was designed to accrue 14
patients. If none of those patients experienced a re-
sponse, then the regimen would be considered inac-
tive, and the study would be closed. If at least 1 of the
ﬁrst 14 patients responded, then an additional 16 pa-
tients (for a cumulative total of 30 patients) would be
accrued. If  2 of those 30 patients responded, then
the regimen would be rejected as inactive, and the
study would be closed to limit the number of patients
exposed to an inactive and possibly toxic treatment. In
contrast, if  3 of the 30 patients had responses, then
accrual would continue until the ﬁnal enrollment of a
total of 42 patients; in this stage of the trial, the regi-
men would be rejected as inactive if  4 patients
responded.
Using this design, under the null hypothesis, the
likelihood of closing the trial after the ﬁrst stage was
0.49, whereas the likelihood of closing the trial after
the second stage was 0.83. Although survival is not an
endpoint in Phase II studies, survival rates were cal-
culated and plotted according to the Kaplan–Meier
method.
Patients
Eligibility criteria included histologically proven RCC,
metastatic disease that progressed after a ﬁrst-line
immunotherapy treatment, measurable disease, an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status  2, age  18 years and  70 years, life
expectancy  12 weeks, and written informed consent
obtained according to institutional requirements. Pa-
tients also were required to have adequate organ func-
tion, which was deﬁned by the following: white blood
cell count  3000/L, platelet count  100,000/L,
hemoglobin levels  9.5 g/dL, bilirubin levels  1.5
mg/dL, alanine and aspartate aminotransferase levels
 3 times the upper limit of normal, and creatinine
levels  2.0 mg/dL.
Exclusion criteria included nonmeasurable dis-
ease; previous treatment with any kind of chemother-
apy; the presence of central nervous system metasta-
ses; signiﬁcant comorbidity, including uncontrolled
diabetes; a history of severe coronary artery disease or
myocardial infarction within the last 6 months; psy-
chiatric conditions that had the potential to interfere
with the treatment schedule or compromise the pa-
tient’s ability to consent to treatment; and a history of
metastatic disease within the previous 5 years (except
for localized, nonmelanomatous skin carcinoma or
cervical carcinoma in situ). Pregnant or lactating
women also were excluded from enrollment into the
study. Finally, palliative radiotherapy (only for pa-
tients with symptomatic bone metastases) and the
administration of intravenous bisphosphonates were
allowed.
Treatment
Treatment involved the administration of gemcitabine
at a dose of 1000 mg/m2 intravenously on Days 1 and
8 every 21 days and L-OHP at a dose of 90 mg/m2
intravenously on Day 1 every 21 days. Treatment was
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administered for a minimum of two cycles before re-
sponse evaluation. In patients who received more
than two cycles, disease reevaluation was performed
after every two cycles.
Computed tomography scans represented the
only allowed assessments of disease status both at
baseline and at each reevaluation. Treatment was ad-
ministered mainly, but not exclusively, on an outpa-
tient basis.
Response and Toxicity Criteria
Response to treatment, which was calculated from the
start of the current study, was assessed according to
the Response Evaluation Criteria in Solid Tumors,21
which are based on the evaluation of both target and
nontarget lesions. Target lesions are deﬁned as all
measurable lesions per organ, representative of all
involved organs, whereas nontarget lesions include all
measurable lesions that are not included as target
lesions as well as all nonmeasurable lesions.
Brieﬂy, a complete response (CR) was deﬁned as
the complete disappearance of all known target and
nontarget lesions. A partial response (PR) was deﬁned
either as the complete disappearance of all target le-
sions with nontarget lesions exhibiting the character-
istics of an incomplete response/stable disease (SD) or
as a decrease of  30% in the sum of the longest
dimensions of all target lesions (relative to the base-
line sum of the longest dimensions) without progres-
sion of nontarget lesions.
Progressive disease (PD) was deﬁned as either an
increase of  20% in the sum of the longest dimen-
sions of target and/or nontarget lesions or the appear-
ance of any new lesion(s). SD was deﬁned as disease
that did not meet the criteria for CR, PR, or PD. In
assigning a CR or a PR, changes in tumor measure-
ments were conﬁrmed by repeating tumor assessment
no less than 4 weeks after the criteria for response ﬁrst
were met. Chemotherapy-related toxic effects were
recorded after each treatment cycle and at the end of
treatment and were graded according to the National
Cancer Institute Common Toxicity Criteria (Version
3.0).22
RESULTS
Patient Demographics
Forty-two patients were enrolled in the 3 phases of the
current study and were treated from April 2000 to
January 2003. Thirty-one patients were men (73.80%),
and 11 were women (26.19%). Median patient age was
62.5 years (average, 61.5 years; range, 45–70 years).
The ECOG performance status was 0 in 8 patients
(19.04%), 1 in 28 patients (66.66%), and 2 in the re-
maining 6 patients (14.28%). With regard to the sites of
disease at the time of enrollment, the majority of
patients (28 of 42; 66.66%) presented with  2 meta-
static sites; overall, lung metastases represented the
most common type of metastatic disease and were
evident in 31 patients (73.80%).
All patients had been treated previously with one
of the following immunotherapy regimens: very low
doses of subcutaneous IL-2 plus interferon- (n  29;
69.04%), high doses of subcutaneous IL-2 plus inter-
feron- (n  11; 26.19%), or interferon- alone (n  2;
4.76%). Furthermore, 28 patients (66.66%) also under-
went nephrectomy. Patient characteristics are sum-
marized in Table 1.
Response to Treatment
All enrolled patients were evaluable for response. No
CRs were recorded; however, 6 patients obtained a PR
(objective response rate, 14.28%; 95% conﬁdence in-
terval, 5.43–28.5%). In four patients, responses were
recorded at the ﬁrst disease evaluation, which was
performed at the conclusion of the ﬁrst two treatment
cycles; in the remaining two patients, responses were
evaluated after completion of the fourth treatment
cycle. Eleven patients (26.19%) had only temporary SD
as their best response, whereas the remaining 25 pa-
tients (59.52%) experienced disease progression de-
spite receiving treatment.
The clinical characteristics of the six patients who
experienced responses are reported in Table 2. Figure
1 shows representative computed tomography scans
from a patient who had complete disappearance of
lung metastases, although this patient still presented
with abdominal lymph node metastases as well as a
renal primary tumor at the time of reevaluation.
The median time to progression (TTP) was 2.5
months (mean, 3.86 months; range, 1.5–11 months),
and the median overall survival was 9.5 months
(mean, 10.46 months; range, 4–23 months). TTP and
overall survival curves are shown in Figure 2. As ex-
pected, survival was signiﬁcantly longer for patients
who experienced responses (median, 20.25 months;
mean, 20.08 months; range, 18–23 months) compared
with patients who did not (median, 8 months; mean,
8.86 months; range, 4–19.5 months).
Toxicity
A median of 2 cycles of treatment per patient (mean,
3.3 cycles; range, 1–10 cycles) were administered;
treatment generally was well tolerated, and only 1
episode of Grade 4 toxicity was observed. This Grade 4
toxicity, which was noted in a 65-year-old male pa-
tient, was a pulmonary embolism that developed
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shortly after the completion of the patient’s second
and ﬁnal chemotherapy cycle; no clear evidence of
deep venous thrombosis was observed. Grade 3 toxic-
ities included myelosuppression and neuropathy;
other, less severe (i.e., Grade 2) side effects included
nonneutropenic fever, nausea/emesis, mucositis, di-
arrhea, anorexia, asthenia/fatigue, elevated blood
urea nitrogen levels, and transiently increased creati-
nine levels.
Adverse events noted in the current study are
summarized in Table 3. Neither treatment withdraw-
als nor dose reductions were necessary. One patient
had a 1-week delay in the administration of his fourth
(and last) cycle due to persistent Grade 3 neutropenia,
which resolved without the use of hematopoietic
growth factors.
DISCUSSION
The development of active, second-line treatment
protocols is the key to improving the overall survival of
patients affected with RCC. Their survival remains un-
satisfactory at best; in fact, at present, no standard
treatment options are available when patients do not
experience a response or when they develop progres-
sive disease after ﬁrst-line immunotherapy.23 For
these reasons, there is a great need for new ap-
proaches.
Among more recent chemotherapeutic agents,
gemcitabine appears to be the most promising drug
available, in part because it is not a known substrate
for P-glycoprotein,24 which is responsible for the well
known chemoresistance of RCC.25 Recently, the com-
bination of gemcitabine and 5-FU proved to be active
against RCC,14 but no further improvements were re-
corded when either cisplatin,19 interferon, or IL-218
was added; furthermore, a Phase II study of gemcit-
abine, 5-FU, and oral thalidomide resulted in an un-
acceptably high incidence of thromboembolic compli-
cations.20
In the current Phase II study, we tested the com-
bination of gemcitabine with L-OHP in a population of
chemotherapy-naı¨ve patients with RCC who experi-
enced disease progression after ﬁrst-line immuno-
therapy. The regimen was well tolerated, with few
unexpected toxicities: myelosuppression and neurop-
athy were the most common side effects recorded. In
terms of antitumor efﬁcacy, 6 patients (14.28%) had
objective responses, suggesting that the regimen pos-
sesses a certain level of activity.
TABLE 1
Patient Characteristics
Characteristic No. of patients (%)
Age (yrs)
Median 62.5
Range 45–70
Gender
Male 31 (73.80)
Female 11 (26.19)
ECOG performance status
0 8 (19.04)
1 28 (66.66)
2 6 (14.28)
Histology
Clear cell carcinoma 30 (71.42)
Papillary carcinoma 10 (23.80)
Undifferentiated carcinoma 1 (2.38)
Sarcomatoid carcinoma 1 (2.38)
Nuclear grading (Fuhrman criteria)
Grade 1 8 (19.04)
Grade 2 12 (28.57)
Grade 3 18 (42.85)
Grade 4 4 (9.52)
No. of disease sites
1 14 (33.33)
2 20 (47.61)
 3 8 (19.04)
Disease site
Lung 31 (73.80)
Lymph nodes 21 (50.00)
Kidney 14 (33.33)
Liver 7 (16.66)
Bone 5 (11.90)
Skin 1 (2.38)
Prior treatment
Nephrectomy 28 (66.66)
Immunotherapy 42 (100.00)
Previous best response to immunotherapy
Complete response 0 (0.00)
Partial response 8 (19.04)
Stable disease 11 (26.19)
Progressive disease 23 (54.76)
Duration of previous immunotherapy (mos)
Median 5
Range 1–18
ECOG: Eastern Cooperative Oncology Group.
TABLE 2
Characteristics of the Six Patients Who Achieved Responses
to Treatment
Gender
Age
(yrs) Metastatic site(s) Site(s) of response
Response
duration
(mos)
Male 66 Lung, kidney, abdominal LNs Lung 8.0
Female 45 Lung Lung 8.0
Male 67 Kidney, lung Lung 4.5
Male 55 Abdominal LNs Abdominal LNs 4.5
Male 55 Abdominal LNs, liver Abdominal LNs, liver 3.5
Male 51 Kidney, abdominal LNs, lung Abdominal LNs, lung 9.0
LNs: lymph nodes.
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The results of the current study are more favor-
able than the results that have been reported for gem-
citabine alone (i.e., a 6% overall response rate in a
small National Cancer Institute of Canada Phase II
study11 and an 8.1% response rate in a numerically
adequate Dutch Phase II study12). However, our ﬁnd-
ings are in agreement with results reported by a group
at the University of Chicago; in 2 distinct Phase II
studies, those investigators tested the antitumor activ-
ity of gemcitabine combined with continuous-infu-
sion 5-FU alone or with continuous-infusion 5-FU
plus immunotherapy (IL-2 and interferon-) and
found overall response rates of 17% and 14.6%, re-
spectively.14,18
At least two other gemcitabine-based Phase II
studies have reported higher response rates (31% in a
single-agent feasibility study15 and 28% for the com-
bination of gemcitabine, IL-2, and interferon-.17)
than the one noted in the current study. However, the
small number of patients enrolled in those studies (16
and 18, respectively) may be indicative of a relevant
bias.
Gemcitabine appeared to be the key drug in the
current study regimen, as was evidenced by the poor
results obtained previously with L-OHP in patients
with RCC. In fact, no objective responses were ob-
served in either a small pilot study of the FOLFOX-4
(5-FU, leucovorin, and L-OHP) regimen26 or a larger (n
 59) Phase II study of the same regimen.27
In conclusion, our results suggest a certain level
of activity, with an acceptable toxicity proﬁle, for the
FIGURE 2. Progression-free survival and overall survival (inset) curves for
the entire patient population treated in the current Phase II study.
FIGURE 1. (A) Pretreatment and (B) posttreatment chest computed tomography scans from a male patient age 66 years with lung metastases from renal cell
carcinoma; arrows indicate pulmonary metastatic disease sites and pleural effusion. Treatment yielded a complete response in the lung, with extrapulmonary disease
persisting. According to the Response Evaluation Criteria in Solid Tumors, this patient had achieved a global partial response.
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combination of gemcitabine and L-OHP in patients
with immunotherapy-resistant advanced RCC; how-
ever, as reported by many other investigators, these
results remain unsatisfactory in terms of both ob-
jective response and survival. Consequently, our
regimen should not be considered to be standard
treatment for patients with immunotherapy-refrac-
tory RCC, and newer therapeutic strategies should
be pursued within adequately large Phase I and II
studies of new agents.
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